Pictet Asset Management Sa Nektar Therapeutics Transaction History

Pictet Asset Management Sa

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$0.64 - $3.15 $1.64 Million - $8.08 Million	2,564,806 Added 221.89%	3,720,679 $2.6 Million
Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $600,179 - $1.27 Million	295,655 Added 34.37%	1,155,873 $2.61 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $1.57 Million - $2.65 Million	515,975 Added 149.89%	860,218 $2.75 Million
Q2 2022 Aug 09, 2022	BUY	$3.17 - $6.17 $1.05 Million - $2.04 Million	330,476 Added 2400.49%	344,243 $1.31 Million
Q3 2021 Nov 12, 2021	BUY	$13.07 - $18.84 $179,934 - $259,370	13,767 New	13,767 $247,000

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $193M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Pictet Asset Management Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet Asset Management Sa with notifications on news.